J. Bitzel and D.M. Patel report employment with Johns Hopkins University. D.C. Crews reports employment with Johns Hopkins University; consultancy for Yale New Haven Health Services Corporation Center for Outcomes Research and Evaluation (CORE); research funding from Baxter International and Somatus, Inc.; honoraria from Maze Therapeutics; and other interests or relationships with Board of Directors of National Kidney Foundation of Maryland/Delaware, Council of Subspecialist Societies of the American College of Physicians, Executive Councilor of the American Society of Nephrology, and Nephrology Board of the American Board of Internal Medicine. D.C. Crews reports advisory or leadership roles for Advisory Group, Health Equity Collaborative, Partner Research for Equitable System Transformation after COVID-19 (PRESTAC); Associate Editor for Kidney360; Co-Chair of Bayer HealthCare Pharmaceuticals Inc. Patient and Physician Advisory Board Steering Committee for Disparities in Chronic Kidney Disease Project; Editorial Boards for CJASN, JASN, and the Journal of Renal Nutrition; and Optum Labs. D.M. Fine reports employment with Johns Hopkins University School of Medicine, consultancy for Fresenius Kidney Care Medical Advisory Board and GlaxoSmithKline DSMB, and advisory or leadership role for Medical Advisory Board—Fresenius Medical Corporation. T. Grader-Beck reports employment with Johns Hopkins, consultancy for IQVIA and Novartis, and advisory or leadership role for Novartis. M.E. Grams reports employment with New York University; advisory or leadership roles for the American Journal of Kidney Diseases, the American Society of Nephrology Publication Committee, CJASN, the JASN Editorial Fellowship Committee, the National Kidney Foundation Scientific Advisory Board, the Kidney Disease: Improving Global Outcomes Executive Committee (co-chair elect), and the United States Renal Data System Scientific Advisory Board; grant funding from NKF, which receives funding from multiple pharmaceutical companies; grant funding from NIH; payment from academic institutions for grand rounds; and payment from NephSAP. C.R. Parikh reports employment with Johns Hopkins University School of Medicine; consultancy for Genfit Biopharmaceutical Company; ownership interest in Renaltix AI; research funding from the National Heart, Lung and Blood Institute (NHLBI) and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); and advisory or leadership roles for Genfit Biopharmaceutical Company and Renalytix. S. Thavarajah reports employment with Johns Hopkins University School of Medicine and other interests or relationships with the National Kidney Foundation as a National Board member and member of the national scientific advisory board and with the local NKF chapter medical advisory board and board of advisors. S. Thavarajah reports advisory or leadership roles as Medical Advisory Board NKF of Maryland immediate past chair and as previous vice chair of Maryland Kidney Commission 2021–2022, and now chair. S. Thavarajah reports honoraria as a speaker for a CME program conducted by the NKF in December 2020—the NKF had funding for the program and provided a speaker's honorarium to each of the faculty speakers. The original funding was from Bayer, but the honorarium came through the NKF.